Virax raises $3.25 million
Thursday, 13 January, 2005
Virax (ASX:VHL) has secured $3.25 million of the $4 million it was aiming to raise through a non-renounceable share purchase plan.
The funds will go towards the company's hepatitis B and prostate cancer programs. In late December 2004, Virax announced that a preclinical trial of a preliminary drug developed using its Co-X-Gene technology had induced an immune response against prostate cancer cells.
The company plans to commence animal toxicology work this year, with a view to moving into human trials.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
